DPP-4 Inhibitor Protects Kidneys From Cyclosporine Toxicity Through GLP-1 Pathway
The DPP-4 inhibitor omarigliptin combined with shikonin protected against cyclosporine-induced kidney damage by preserving GLP-1 signaling and reducing inflammation and oxidative stress.
Quick Facts
What This Study Found
Omarigliptin/shikonin combination protected against cyclosporine nephrotoxicity by preserving GLP-1 signaling, reducing inflammation, and mitigating oxidative stress in kidney tissue.
Key Numbers
Specific dose levels and kidney function measurements were analyzed but not detailed in the available abstract.
How They Did This
Animal study testing omarigliptin (DPP-4 inhibitor) and shikonin combination in cyclosporine-induced nephrotoxicity model. Assessed kidney function, GLP-1 levels, inflammatory markers, and oxidative stress.
Why This Research Matters
Cyclosporine kidney damage limits its long-term use in transplant patients. If DPP-4 inhibitors can protect kidneys through GLP-1 preservation, transplant patients could use cyclosporine more safely for longer.
The Bigger Picture
The GLP-1/DPP-4 axis is revealing kidney-protective properties across many contexts — from diabetic nephropathy to drug-induced toxicity. This expanding evidence suggests GLP-1-based therapies could become standard kidney-protective agents in various clinical settings.
What This Study Doesn't Tell Us
Animal study. Combination therapy adds complexity. The specific contributions of omarigliptin vs shikonin need dissection. Human translation requires clinical trials in transplant patients.
Questions This Raises
- ?Should transplant patients on cyclosporine receive DPP-4 inhibitors for kidney protection?
- ?Does GLP-1 preservation provide kidney protection beyond what its glucose-lowering effects explain?
- ?Could GLP-1 receptor agonists provide even stronger kidney protection than DPP-4 inhibitors in this setting?
Trust & Context
- Key Stat:
- GLP-1 protects kidneys DPP-4 inhibitor-preserved GLP-1 signaling reduced cyclosporine kidney damage through anti-inflammatory and antioxidant mechanisms
- Evidence Grade:
- Preliminary evidence: animal study demonstrating kidney protection through GLP-1 pathway preservation during immunosuppressive therapy.
- Study Age:
- Published in 2025. Expands GLP-1 kidney protection evidence to drug-induced nephrotoxicity.
- Original Title:
- Omarigliptin/shikonin combination alleviates cyclosporine-induced nephrotoxicity: The role of sirtuin 1, glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and p38/ERK/JNK MAPKs.
- Published In:
- Human & experimental toxicology, 44, 9603271251394693 (2025)
- Authors:
- Abdallah, Marwa H, Atia, Hanan Abdelmawgoud, Elariny, Hemat A, Khalifa, Amany M, Saleh, Asmaa, Kabel, Ahmed M
- Database ID:
- RPEP-09730
Evidence Hierarchy
Frequently Asked Questions
How does a DPP-4 inhibitor protect kidneys?
DPP-4 inhibitors prevent the breakdown of GLP-1, a peptide hormone with anti-inflammatory and protective properties. By maintaining higher GLP-1 levels, the kidneys are better protected from the toxic effects of cyclosporine.
Could this help transplant patients?
Potentially. Cyclosporine kidney damage is a major problem in transplant medicine. If DPP-4 inhibitors can protect kidneys while patients take cyclosporine, it could allow longer and safer use of this essential anti-rejection drug.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09730APA
Abdallah, Marwa H; Atia, Hanan Abdelmawgoud; Elariny, Hemat A; Khalifa, Amany M; Saleh, Asmaa; Kabel, Ahmed M. (2025). Omarigliptin/shikonin combination alleviates cyclosporine-induced nephrotoxicity: The role of sirtuin 1, glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and p38/ERK/JNK MAPKs.. Human & experimental toxicology, 44, 9603271251394693. https://doi.org/10.1177/09603271251394693
MLA
Abdallah, Marwa H, et al. "Omarigliptin/shikonin combination alleviates cyclosporine-induced nephrotoxicity: The role of sirtuin 1, glucagon-like peptide-1, HMGB1/RAGE/TLR4 signaling, and p38/ERK/JNK MAPKs.." Human & experimental toxicology, 2025. https://doi.org/10.1177/09603271251394693
RethinkPeptides
RethinkPeptides Research Database. "Omarigliptin/shikonin combination alleviates cyclosporine-in..." RPEP-09730. Retrieved from https://rethinkpeptides.com/research/abdallah-2025-omarigliptinshikonin-combination-alleviates-cyclosporineinduced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.